Arvinas, Inc. (ARVN) · Nov 3, 2026 · Earnings

Arvinas earnings miss as revenue vanishes and pipeline data loom

Miss — Revenue $0.5M vs ~$16.9M consensus

Arvinas earnings show a sharp revenue reset after the Rigel deal, with lower expenses and upcoming clinical data keeping the story alive.

Arvinas is transitioning from a collaboration-revenue model toward a clinical-stage pipeline company after licensing vepdegestrant to Rigel, with ARV-393, ARV-027 and ARV-6723 now carrying more of the business story. The Rigel transaction was already expected to remove much of the old Pfizer-related revenue, while prior company plans already pointed to 2026 pipeline milestones and a cash runway into the second half of 2028.

The quarter missed the financial bar because revenue reset faster than consensus expected. Revenue fell to just $0.5 million from $41.9 million a year earlier, versus published consensus of roughly $16.9 million; the remaining revenue was only sales-based royalties from the Rigel license, while prior Pfizer collaboration revenue no longer recurs.

Q3 2026Q3 2025Consensus
Revenue (Financial Highlights)$0.5M$41.9M$16.9M
Diluted EPS (Income Statement)$(0.82)$(0.48)$(0.87)
GAAP R&D (Income Statement)$46.9M$64.7M
Cash, equivalents, restricted cash and marketable securities (Cash Position)$558.9M$685.4M at Dec. 31, 2025

Lower spending partly cushions the revenue miss. GAAP R&D fell 28% year over year and G&A fell 40%, producing a diluted loss of $0.82 per share that was modestly better than the roughly $0.87 consensus. The savings are real, but they mainly reflect a smaller operating footprint and reduced spending on the former vepdegestrant program rather than a new source of growth.

The business remains funded, but the pipeline—not this quarter's financials—is the next test. Arvinas says its $558.9 million liquidity position funds planned operations into the second half of 2028, while the filing keeps Q4 2026 ARV-393 clinical data and additional ARV-027 and ARV-6723 milestones in view. Those milestones were directionally expected; the filing advances the calendar but does not yet provide human efficacy data that would materially rewrite the clinical story. 〔0〕

Bottom line: This is a financial miss caused by the post-Rigel revenue reset, softened by tighter spending and a preserved cash runway. It matters less as an earnings event than as a bridge to the upcoming clinical readouts, which still have to validate the pipeline story.

What to watch next

Q4 2026 ARV-393 clinical data presentation

Original filing on SEC EDGAR

Arvinas earnings miss as revenue vanishes and pipeline data loom | ARVN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.